Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

BMS would make payments with respect to the CVRs only if the Food and Drug Administration’s approval of certain Celgene products was received by a specified date. Ultimately, the approval was received ...

Bristol Myers Squibb (NYSE ... “Building on momentum from the recent U.S. Food and Drug Administration’s approval of COBENFY for the treatment of schizophrenia in adults, we’re pleased ...

Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ...

Bristol Myers Squibb (NYSE: BMY) today announced that new clinical ... “Building on momentum from the recent U.S. Food and Drug Administration’s approval of COBENFY for the treatment ...

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 ...